The ecosystem of good bacteria that lives in every human body - or the human 'microbiome' - is a hot topic in science. Predictably, therefore, lots of biotech companies have crowded into the market place for microbiome-inspired products. Yet Aim-traded OptiBiotix Health (OPTI) is different - it targets healthy food supplements rather than pharmaceutical therapies.
- Innovative technology
- Operating in potentially massive markets
- In partnership with big companies
- Royalty payments starting to flow
- No City forecasts
- In a competitive market place
Using its two technology platforms - OptiScreen and OptiBiotic - OptiBiotix has churned out a pipeline of gut bacteria that have a proven impact on weight and cholesterol levels. The plan is to incorporate these bacteria into new health foods and supplements as treatments for obesity and diabetes. In theory, the platforms have the potential to generate bacteria to treat a huge range of diseases and OptiBiotix has recently established a skin healthcare subsidiary.